Clinical Study Verifies HSRx OTC Drug Product For Joint Pain Delivers Faster And More Effective Treatment Results Than A Current Market Leading Product

Thursday, November 10, 2016 Drug News
Email Print This Page Comment bookmark
Font : A-A+

TUCSON, Ariz., Nov. 10, 2016 /PRNewswire/ -- HSRx Biopharmaceutical, a leading developer of proprietary OTC drugs, announced

that an independently conducted clinical study has demonstrated its new product, OsteoRx™, outperformed Osteo Bi-Flex Triple Strength® in alleviating pain and increasing range of motion in patients suffering from joint pain. OsteoRx™ is a new joint health
system comprised of an OTC topical analgesic combined with a natural antioxidant to support overall joint health.

An independent clinical research organization conducted the randomized, double-blind, placebo-controlled study by enrolling 60 patients diagnosed with mild to moderate osteoarthritis of the knee. Measurements in the level of pain and range of motion in the affected knee were recorded over a 14-day period for each patient. Independent statistical experts determined that, over the course of the study, patients using OsteoRx™ experienced significantly higher reduction in pain and significantly greater improvement in range of motion than did patients using the competing product.

After 48 hours, the average pain reduction for OsteoRx™ users was nearly three times greater than for patients using the competing brand. At seven days, average pain reduction was more than three times greater than the competition. After 14 days of treatment, average pain reduction was more than twice as large as the competition.

After just 24 hours, patients using OsteoRx™ experienced an average improvement in range of motion that was more than twice as large as the competition. At 72 hours, OsteoRx™ results were nearly five and a half times better. After 14 days of treatment, the average improvement was still nearly twice as large as the competition.

"Joint pain associated with normal aging and over-exercising is extremely common," said Thomas Sullivan, Jr., Chief Executive Officer of HSRx Biopharmaceutical.  "Research funded by U.S. National Academy of Medicine shows that 70 million adults suffer from joint pain, making it the most prevalent source of pain.  With the dramatic treatment outcomes delivered by OsteoRx™, demand for our product should be significant."

"All HSRx OTC drug products are designed to become category leaders," noted Frank Parise, the company's Chief Financial Officer. "We demonstrated superior treatment outcomes with our acne product in a head-to-head clinical trial against the market-leader, and now we've done the same with OsteoRx™. We are actively seeking the best-suited licensees having resources and marketing expertise to maximize sales for each of our products in the U.S. and globally."

About HSRx Biopharmaceutical

HSRx Biopharmaceutical, an Arizona-based biopharmaceutical company, is a leader in the development of monographed OTC Drug products that are formulated with proprietary natural ingredients. The proprietary formulations support long product patent lives. Each HSRx OTC drug product is proven in independently conducted clinical studies to provide superior treatment outcomes. The clinical studies support powerful marketing claims. For more information, click on


To view the original version on PR Newswire, visit:

SOURCE HSRx Biopharmaceutical

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store